| WANG Hai-rong,ZHU Wei-guo,QIN Shan-shan,et al.A randomized, controlled study of different chemotherapy regimens combined with postoperative radiotherapy for patients with high-risk early stage cervical cancer[J].Chinese Journal of Radiological Medicine and Protection,2013,33(1):50-54 |
| A randomized, controlled study of different chemotherapy regimens combined with postoperative radiotherapy for patients with high-risk early stage cervical cancer |
| Received:August 13, 2012 |
| DOI：10.3760/cma.j.issn.0254-5098.2013.01.013 |
| KeyWords:Early stage cervical cancer Concurrent chemoradiotherapy Overall survival rate Recurrence-free survival rate |
| FundProject:江苏省淮安市科技支撑计划(HAS2010030) |
| Author Name | Affiliation | E-mail | | WANG Hai-rong | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | ZHU Wei-guo | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | jshazwg@126.com | | QIN Shan-shan | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | GUO Jia-ni | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | WANG Hai-dong | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | LI Tao | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | TAO Guang-zhou | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | JI Fu-zhi | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | ZHOU Xi-lei | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | HAN Ji-hua | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | | | YU Chang-hua | First Hospital of Huaian City, Nanjing Medical University, Huaian 223300, China | |
|
| Hits: 6293 |
| Download times: 3287 |
| Abstract:: |
| Objective To investigate whether docetaxel plus cisplatin combined with radiotherapy(TP-R) compared with cisplatin-only combined radiotherapy(C-R) could increase overall survival and recurrence-free survival on patients with high-risk early stage cervical cancer.Methods Eligible high-risk patients with stage Ⅰb and Ⅱa cervical cancer were randomly assigned to C-R and TP-R group. The external irradiation dose was 46-54 Gy, following 12-24 Gy of intracavitary brachytherapy. In C-R group, chemotherapy regimens consisted of cisplatin 30 mg/m2 (weekly, with 5 cycles). In TP-R group, chemotherapy regimens consisted of cisplatin 25 mg/m2 and of docetaxel 25 mg/m2 (weekly, with 5 cycles). Results A total of 285 patients entered final analysis. There were 140 cases in C-R group and 145 in TP-C group, respectively. The 5-year overall survival rate was 74.3% in C-R group and 82.8% in TP-R group(P>0.05). The hazard ratio for death on TP-R group was 0.65(95%CI: 0.39-1.09). The 5-year recurrence survival rates were 69.3% in C-R group and 79.3% in TP-R group(P>0.05), respectively. And the hazard ratio for death on TP-R group was 0.64(95%CI: 0.40-1.03). Recurrence rates were similar in two groups(P>0.05).Rate of ≥ grade 3 adverse events was higher in TP-R group(χ2=6.88, P<0.05). Conclusions Docetaxel plus cisplatin combined with radiotherapy fails to increase overall survival rates compared with cisplatin-only combined with radiotherapy for patients with high-risk stageⅠb and Ⅱa cervical cancer, though there is a trend to increase recurrence-free survival rates. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
